Nicolas Lecomte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicolas Lecomte has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Christine Iacobuzio-Donahue
The David M Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY
51 shared publications - Dana Pe’er
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
28 shared publications - Olivera Grbovic-Huezo
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York
28 shared publications - Ronan Chaligne
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
28 shared publications - Alexander Ferrena
Institute for Clinical and Translational Research, Albert Einstein College of Medicine, New York, USA
27 shared publications - Anna Hudson
Section of Virology and Immunotherapy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
27 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S1 shows frequency distribution of estimated CCF values for all major driver genes selected in this study.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S1 shows frequency distribution of estimated CCF values for all major driver genes selected in this study.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S11 shows 2 × 2 contingency table to calculate p-value for pathway analysis.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S11 shows 2 × 2 contingency table to calculate p-value for pathway analysis.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S4 shows list of genetic details and clonality of KRAS and TP53 mutations in our PDAC cohort.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S4 shows list of genetic details and clonality of KRAS and TP53 mutations in our PDAC cohort.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S7 shows list of significantly amplified or deleted genes for each type of treatment plan based on GISTIC2.0.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S7 shows list of significantly amplified or deleted genes for each type of treatment plan based on GISTIC2.0.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S10 shows comparison of the distribution of CCF estimates between primary and metastatic tumors at the patient level.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S10 shows comparison of the distribution of CCF estimates between primary and metastatic tumors at the patient level.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
We performed whole-exome sequencing of 250 unique tumor tissues from 30 multi-region sampled pancreatic cancer research autopsies from patients diagnosed with advanced-stage disease. Convergent evolution within the TGFβ pathway is a common feature of advanced-stage disease. However, SMAD4 inactivation is more common among de novo metastatic pancreatic ductal adenocarcinomas (PDAC), whereas inactivation of TGFβ surface receptors is more common among locally advanced nonmetastatic cancers. These differences in metastatic propensity were orthogonally validated in mice by orthotopic injections of PDAC organoids with SMAD4 versus TGFBR2 inactivation. No functionally deleterious driver gene mutations were identified that were attributed to treatment, although irradiated PDACs had significantly greater genomic complexity and distinct mutational signatures compared with PDACs managed by chemotherapy. These findings provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, potentially serving as a biomarker of borderline resectable or locally advanced PDACs most likely to benefit from neoadjuvant chemoradiation.Significance:This study fills an important gap in knowledge related to the characteristics of genomic alterations of advanced-stage disease. We expect that these findings will serve as a baseline reference set to identify mechanisms of resistance as novel therapies continue to become available for patients with PDAC.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
We performed whole-exome sequencing of 250 unique tumor tissues from 30 multi-region sampled pancreatic cancer research autopsies from patients diagnosed with advanced-stage disease. Convergent evolution within the TGFβ pathway is a common feature of advanced-stage disease. However, SMAD4 inactivation is more common among de novo metastatic pancreatic ductal adenocarcinomas (PDAC), whereas inactivation of TGFβ surface receptors is more common among locally advanced nonmetastatic cancers. These differences in metastatic propensity were orthogonally validated in mice by orthotopic injections of PDAC organoids with SMAD4 versus TGFBR2 inactivation. No functionally deleterious driver gene mutations were identified that were attributed to treatment, although irradiated PDACs had significantly greater genomic complexity and distinct mutational signatures compared with PDACs managed by chemotherapy. These findings provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, potentially serving as a biomarker of borderline resectable or locally advanced PDACs most likely to benefit from neoadjuvant chemoradiation.Significance:This study fills an important gap in knowledge related to the characteristics of genomic alterations of advanced-stage disease. We expect that these findings will serve as a baseline reference set to identify mechanisms of resistance as novel therapies continue to become available for patients with PDAC.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S8 shows list of significantly amplified or deleted PDAC drivers categorized by treatment type and sample origin (primary versus metastatic) based on GISTIC2.0.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S8 shows list of significantly amplified or deleted PDAC drivers categorized by treatment type and sample origin (primary versus metastatic) based on GISTIC2.0.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S2 shows sample information and sequencing statistics.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S2 shows sample information and sequencing statistics.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S6 shows cosine similarity between de novo and already known signatures.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S6 shows cosine similarity between de novo and already known signatures.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S5 shows samples exhibiting multiple KRAS alleles and their corresponding CCF values.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S5 shows samples exhibiting multiple KRAS alleles and their corresponding CCF values.